Evaluating the Therapeutic Efficacy of Rifaximin in Patients With Diabetic Gastroparesis Using Bloating as the Primary Endpoint
Latest Information Update: 07 May 2025
At a glance
- Drugs Izencitinib (Primary)
- Indications Diabetic gastroparesis
- Focus Therapeutic Use
Most Recent Events
- 27 Apr 2025 Status changed from recruiting to suspended. (Sponsor discontinued placebo. Unable to meet enrollment goals.)
- 22 Jan 2025 Planned End Date changed from 1 Dec 2024 to 1 Aug 2025.
- 22 Jan 2025 Planned primary completion date changed from 1 Dec 2024 to 1 Mar 2025.